Pfizer settles last whistleblower suit for $14.5M; NJ offers $3.6M retraining for laid-off pharma workers;

> Pfizer ($PFE) agreed to pay $14.5 million to settle the last of 10 whistleblower lawsuits, wrapping up allegations that it marketed its Detrol drug for off-label use as a treatment for enlarged prostate and bladder obstruction. News

> The government of New Jersey said it would deliver $3.6 million in federal funding for retraining programs for laid-off pharma workers. Report

> Valeant Pharmaceuticals ($VRX) obtained $2 billion in new financing to refinance existing bridge loans and revolving debt. Item

> Bulgarian generics maker Sopharma plans to list its shares in Warsaw as well as on the Sofia bourse where they are now traded. Article

> Watson Pharmaceuticals ($WPI) won the FDA nod for a smaller-sized version of its testosterone patch Androderm. Story

> Janssen Therapeutics, a unit of Johnson & Johnson ($JNJ), got the FDA's blessing for a label update on its HIV drug Prezista to include positive data from a recent trial in treatment-naive patients. News

> Shanghai Modern Pharmaceutical plans to invest 277 million yuan ($43.4 million) to build a production base in Henan province. Article

> Actelion won its motion for a new trial in a licensing dispute with Asahi Kasei Pharma over the drug compound fasudil. Report

And Finally... Wal-Mart Stores won't offer health insurance to many part-time workers and will charge tobacco users more for their coverage. Story

Suggested Articles

A group of senators is asking the FTC to take a careful look at pharma mergers given the cost of drugs in the U.S.

Life’s been tough for J&J's prostate cancer med Erleada in its battle with Pfizer-Astellas’ Xtandi. A new FDA nod could help level the playing field.…

Biogen plans to test its SMA drug Spinraza at a higher-than-approved dose as Novartis' rival gene therapy Zolgensma picks up traction.